EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition

Peng Pi, Zhipeng Zeng, Liqing Zeng, Bing Han, Xizhe Bai, Shousheng Xu

Frontiers in Pharmacology · 03.08.2023 · 14

DOI: 10.3389/fphar.2023.1218059 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 03.08.2023. Verfasst von Peng Pi und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Sports Medicine and Rehabilitation, Beijing Sport University, Beijing, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first broke out in Hubei Province, China, at the end of 2019. It has brought great challenges and harms to global public health. SARS-CoV-2 mainly affects the lungs and is mainly manifested as pulmonary disease. However, one of the biggest crises arises from the emergence of COVID-19-induced fibrosis. At present, there are still many questions about how COVID-19 induced pulmonary fibrosis (PF) occurs and how to treat and regulate its long-term effects. In addition, as an important process of fibrosis, the effect of COVID-19 on epithelial-mesenchymal transition (EMT) may be an important factor driving PF. This review summarizes the main pathogenesis and treatment mechanisms of COVID-19 related to PF. Starting with the basic mechanisms of PF, such as EMT, transforming growth factor-β (TGF-β), fibroblasts and myofibroblasts, inflammation, macrophages, innate lymphoid cells, matrix metalloproteinases and tissue inhibitors of metalloproteinases, hedgehog pathway as well as Notch signaling. Further, we highlight the importance of COVID-19-induced EMT in the process of PF and provide an overview of the related molecular mechanisms, which will facilitate future research to propose new clinical therapeutic solutions for the treatment of COVID-19-induced PF.

Schlagwörter

Stichwörter der Autor:innen

COVID-19SARS-CoV-2epithelial-mesenchymal transitionmolecular mechanismspulmonary fibrosis

Autor:innen und Institutionen

  • School of Sports Medicine and Rehabilitation, Beijing Sport University, Beijing, China.
  • College of Physical Education and Health, East China Normal University, Shanghai, China.
  • School of Sports Engineering, Beijing Sport University, Beijing, China.

Zitieren

APA

Pi, P., Zeng, Z., Zeng, L., Han, B., Bai, X., & Xu, S. (2023). Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1218059

Vancouver

Pi P, Zeng Z, Zeng L, Han B, Bai X, Xu S. Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1218059

BibTeX
@article{Pi2023,
  author = {Pi, Peng and Zeng, Zhipeng and Zeng, Liqing and Han, Bing and Bai, Xizhe and Xu, Shousheng},
  title = {Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1218059}
}
Kostenlos starten →